LABT · Lakewood-Amedex Biotherapeutics Inc. · Share Buybacks
$0.85
-0.09 (-9.39%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has historically incurred recurring operating losses and negative operating cash flows and expects to continue to incur operating losses and consume cash as it executes its business plan. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed financial statements are issued. Because the Company will require additional financing within one year after the date these condensed financial statements are issued and such financing is not considered probable under the provisions of ASC 205-40, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.96M
Shares
2.37M
Volume · Oct 5
254.72K
Avg daily vol (3M)
2.37M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2024-12-31 | $50,000 | Other, filed 2026-09-18 |